Interleukin-6 as a therapeutic target

Human IL6 is a cytokine produced by many cell types that has pleiotropic effects. In agreement, anti-IL6 therapy reduces inflammation, hepatic acute phase proteins, and anemia and has antiangiogenic effects. Blocking IL6 has demonstrated therapeutic efficacy with drug registration in Castleman disea...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2015-03, Vol.21 (6), p.1248-1257
Hauptverfasser:	Rossi, Jean-François, Lu, Zhao-Yang, Jourdan, Michel, Klein, Bernard
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal, Humanized - pharmacology Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - immunology Biomarkers, Tumor C-Reactive Protein - biosynthesis Cancer Castleman Disease - drug therapy Castleman Disease - metabolism Cell Proliferation - drug effects Humans Inflammation - drug therapy Interleukin-6 - antagonists & inhibitors Life Sciences Mice Neoplasms - drug therapy Receptors, Interleukin-6 - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!